GLP-1 Drugs Linked to GI Effects, Uncertain Signals

• by Kathryn Wighton

• April 16, 2026

Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study

• by Soumaya Mrabet, Ghada Saad, Asma Ben cheikh, Mohamed Abu Awad, Imen Halloul, Raida Harbi, Meryam Eloillaf, Imen Akkari, Yosra Hasni, Elhem Ben Jazia

• July 17, 2026

Diabetes and the Metabolic Syndrome as Drivers of Neurodegeneration: Convergent Mechanisms Linking Peripheral Neuropathy and Dementia

• by Masha G. Savelieff, David L. Bennett, Troels S. Jensen, Eva L. Feldman

• July 7, 2026

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

• by Andrea Surnit

• July 13, 2026

• 5 min